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■ LETTER TO THE EDITOR ■
Tamoxifen has been used to treat patients in all stages of
breast cancer. However, the drawback of its estrogen-
mimicking effects on endometrium raises the risk of
endometrial cancer for chronic users as it has been
shown to stimulate growth of some endometrial adeno-
carcinoma cell lines by estrogen receptor-independent
mechanisms in vitro [3]. For long-term Tamoxifen use for
breast cancer patients, development of secretory endo-
metrial adenocarcinoma without estrogen receptors
occurs rarely. According to the keyword searches for
“secretory endometrial adenocarcinoma,” “Tamoxifen,”
and “breast cancer” on MEDLINE of the reports in
English language between 1970s and the end of 2005,
our case is the second one to describe secretory endome-
trial adenocarcinoma associated with Tamoxifen use for
breast cancer.
A 71-year-old woman, multigravida, complained of
postmenopausal vaginal bleeding for 2 to 3 months.
She had undergone right mastectomy for stage II breast
cancer 15 years prior to this admission. Thereafter, she
had received chemotherapy and had been taking oral
10 mg Tamoxifen twice a day for 10 years. Current
medical diseases include hypertension and diabetes
mellitus for 10 years and 2 months, respectively. She
denied any history of estrogen replacement therapy
after menopause at the age of 50 years.
Under vaginal echography, unusual endometrial con-
tour was detected as thick as 21 mm. Her pelvic exami-
nation results revealed no senile changes but a large
uterus as if in 3-months’ gestation. Coupled with atypi-
cal glandular cells on her Papanicolaou smear, fractional
endometrial dilatation and curettage (D&C) revealed
endometrial carcinoma with secretory changes. She
underwent staging laparotomy including total hysterec-
tomy, bilateral salpingoophorectomy, partial omentec-
tomy, sampling of pelvic and paraaortic lymph nodes,
and peritoneal cytology. Grossly, the uterus showed 
no apparent myometrial invasion or generalized thick-
ness of endometrium with multiple polypoid lesions. On
paraffin sections, the tumor measured 1 cm at the great-
est dimension and was estimated at only 5 mm down-
ward invasion into the 3-cm thick myometrium. The
histological morphology revealed a well-differentiated
adenocarcinoma with dominant papillary and gland-
ular patterns, consisting of columnar epithelial cells and
containing intracytoplasmic basal vacuoles (Figure 1),
which was similar to secretory endometrium arising
from atypical complex secretory hyperplasia. Using
immunohistochemical stains, we found exclusively
strong positive results for progesterone receptors, 
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Figure 1. Secretory endometrial adenocarcinoma showing 
a well-differentiated papillary pattern, comprising columnar
epithelial cells with intracytoplasmic basal vacuoles, similar
to the secretory phase of endometrium (hematoxylin and
eosin, 100×).
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but the results were negative for estrogen receptors
(Figures 2 and 3).
Secretory adenocarcinoma is an uncommon variant
of endometrioid adenocarcinoma which usually pres-
ents as a well-differentiated tumor with progesterone
changes and it is difficult to differentiate it from secre-
tory endometrium [1]. The histological pattern com-
prises well-differentiated glands resembling those of
early or midsecretory endometrium. Subnuclear and/or
supranuclear vacuolation is also commonly seen.
There is minimal cellular atypia, stratification, and pleo-
morphism. The intracellular secretions are not mucin
but glycogen. The glands are positive with periodic acid-
Schiff (whether predigested or not); they are partly posi-
tive using alcian blue and negative using Best Carmine.
The cellular features of secretory carcinoma differentiate
it from clear-cell carcinoma, which is more papillary with
more pleomorphic nuclei. Because of its lack of mucin,
it may be differentiated from mucinous carcinoma [2].
Confused identification may occur in patients with
history of recent ovulation or progestin use before 
tissue sampling in what would have otherwise been
atypical hyperplasia or well-differentiated endomet-
rioid carcinoma. A thorough clinical history should be
provided to the pathologist to avoid confusion even
though the prognosis is good for patients with secretory
adenocarcinoma.
As a well-known risk factor of endometrial cancer for
Tamoxifen users, a median Tamoxifen cumulative dose
of 29 g has been suggested as a threshold for the devel-
opment of endometrial carcinoma. The risk of endome-
trial cancer increases two- to three-fold after an exposure
of up to 5 years. In our case, the total cumulative dose
was 73 g and the use was up to 10 years in addition 
to other risk factors such as hypertension and diabetes
mellitus.
Tamoxifen is the most widely prescribed antineo-
plastic drug for the treatment of both localized and
metastatic breast cancer. It is the prototype for a class of
drugs that are referred to as selective estrogen receptor
modifiers, most of which have both estrogenic and
antiestrogenic effects on the female genital tract,
depending on the ambient estradiol concentration and
the menopausal status of the patient. It has been pro-
posed that Tamoxifen has an estrogen agonistic effect
on the vaginal epithelium, the uterine myometrium,
and the endometrium in postmenopausal women.
This may induce benign cystic hyperplasia of the endo-
metrial stroma and cause an increased polyp forma-
tion [3]. The proposed estrogenic effects of Tamoxifen
include prognostically favorable, highly differentiated,
endometrioid carcinomas, compatible with Bochman
Type I.
The genetic predisposition toward endometrial car-
cinoma and endometrial carcinogenesis by Tamoxifen
users is not well known. In recent years, the molecular
genetic alterations associated with Type I endometrial
carcinomas, including mutations in PTEN, K-ras, and
the presence of microsatellite instability, have been
elucidated. These distinct mutations segregated by
histological subtypes rather than Tamoxifen exposure,
and Tamoxifen may only act as initiators of tumorigene-
sis via estrogen agonistic activity in the endometrium [4].
However, it is interesting that the endometrial carcinoma
was negative for estrogen receptors and exclusively
positive for progesterone receptors in this described
case. The results of a few studies have suggested that
Tamoxifen caused a net increase in the progesterone
receptors and sex hormones-binding globulin, and a
significant decrease in the estrogen receptors [5].
Therefore, it is possible that the progestational changes
Figure 3. Immunohistochemical stain for progesterone recep-
tor: positive nuclear staining for tumor cells, normal glands,
and some endometrial stromal cells (40×).
Figure 2. Immunohistochemical stain for estrogen receptor:
negative nuclear staining for tumor and normal glands (40×).
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are related to the use of Tamoxifen, which prompts 
us to postulate that the mechanisms of Tamoxifen
activity that promote endometrial carcinogenesis are
independent of its action as an estrogen agonistic. So 
a more complete understanding of the steroid receptor
status, somatic alterations in oncogenes, and tumor
suppressor genes and inherited susceptibility in endo-
metrial carcinomas associated with Tamoxifen use is
required.
Although the pathogenesis of the striking progesta-
tional changes in the secretory endometrial adenocarci-
noma encountered in this patient remains unclear, this
unusual case was added to the spectrum of Tamoxifen-
associated endometrial carcinomas. It is necessary to
evaluate the stage of pathological changes on the myo-
metrium and endometrium, both before and during the
period of administration of Tamoxifen. In asympto-
matic Tamoxifen users, gynecologic surveillance may
not be recommended but transvaginal ultrasonography
and fractional D&C are indicated in cases of post-
menopausal vaginal bleeding.
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